- 352.204
- +5.356+1.54%
12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session
GainersEl Pollo Loco Holdings (NASDAQ:LOCO) shares increased by 14.1% to $9.81 during Thursday's after-market session. The company's market cap stands at $305.9 million. As per the news, the Q1 earnin
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Thursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an income of $(0.19), smaller than the consensus estimate loss of $(3.55).The company reported sales of $167
12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session
GainersCarvana (NYSE:CVNA) stock increased by 30.8% to $113.95 during Thursday's regular session. The market value of their outstanding shares is at $13.2 billion. The company's, Q1 earnings came out
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out
CG Oncology Price Target Maintained With a $75.00/Share by Cantor Fitzgerald
CG Oncology Price Target Maintained With a $75.00/Share by Cantor Fitzgerald
Elavi Labs Shares Are Trading Higher After the Company Announced the Launch of Elevai Biosciences and Elevai Skincare. Also, the Company Announced Results From Its Licensor's 2022 Preclinical Studies Evaluating the Treatment Effect of EL-22.
Elavi Labs Shares Are Trading Higher After the Company Announced the Launch of Elevai Biosciences and Elevai Skincare. Also, the Company Announced Results From Its Licensor's 2022 Preclinical Studies
Cantor Fitzgerald: The CG Oncology (CGON.US) rating was confirmed and adjusted from an increase to an increase in holdings rating, with a target price of $75.00.
Cantor Fitzgerald: The CG Oncology (CGON.US) rating was confirmed and adjusted from an increase to an increase in holdings rating, with a target price of $75.00.
Cantor Fitzgerald Reiterates Overweight on CG Oncology, Maintains $75 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:CGON) with a Overweight and maintains $75 price target.
CG Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 82.08% Cantor Fitzgerald → $75 Reiterates Overweight → Overweight 04/04/2024 82.08% HC Wainwrig
Mobile-Health Network Solutions Shares Resume Trade
Mobile-Health Network Solutions Shares Resume Trade
Mobile-Health Network Solutions Shares Halted On Circuit Breaker To The Upside, Stock Now Up 21.3%
Mobile-Health Network Solutions Shares Halted On Circuit Breaker To The Upside, Stock Now Up 21.3%
Weitse invests in MSTR up 5.4% Baidu ADR rises 4.8% Guardforce AI rises 3.7% Alibaba ADR rises 3.3%, CrowdStrike rises 2.9%, Tesla rises 1.9%, Reddit rises 1.6%, Apple rises 1.2% Amazon rises 1% Bullfrog AI and BigBear.AI rises 0.9%, and C3.ai rises 0.7%
Weitse invests in MSTR up 5.4% Baidu ADR rises 4.8% Guardforce AI rises 3.7% Alibaba ADR rises 3.3%, CrowdStrike rises 2.9%, Tesla rises 1.9%, Reddit rises 1.6%, Apple rises 1.2% Amazon rises 1% Bullfrog AI and BigBear.AI rises 0.9%, and C3.ai rises 0.7% Google A, Intel, Microsoft rises about 0.6%, and IBM down 0.4% Aster
We Might See A Profit From Amer Sports, Inc. (NYSE:AS) Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Amer Sports, Inc.'s (NYSE:AS) future prospects. Amer Sports, Inc. designs, manufactures, markets, distri
Metagenomi Cut to Neutral From Overweight by JP Morgan
Metagenomi Cut to Neutral From Overweight by JP Morgan
Elevai Biosciences Highlights Preclinical Data Showing Potential Of In-Licensed Asset "EL-22" For The Treatment Of Obesity
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic fea
JP Morgan Downgrades Metagenomi to Neutral, Lowers Price Target to $6
JP Morgan analyst Brian Cheng downgrades Metagenomi from Overweight to Neutral and lowers the price target from $16 to $6.
Metagenomi Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 -7.69% JP Morgan $16 → $6 Downgrades Overweight → Neutral 03/28/2024 223.08% Chardan Capital $2
Little Excitement Around Planet Image International Limited's (NASDAQ:YIBO) Earnings As Shares Take 31% Pounding
Planet Image International Limited (NASDAQ:YIBO) shares have had a horrible month, losing 31% after a relatively good period beforehand. To make matters worse, the recent drop has wiped out a year'
BrightSpring Health Services Increases 2024 Revenue Outlook From $9.35B- $9.50B To $10.30B-$10.80B, Est $9.44B
BrightSpring Health Services Increases 2024 Revenue Outlook From $9.35B- $9.50B To $10.30B-$10.80B, Est $9.44B
BrightSpring Health Services Beats Top-line and Bottom-line Estimates; Raises FY24 Outlook